5 Key Takeaways

• 1

  Vinay Prasad has been appointed as the new director of FDA’s CBER, succeeding Peter Marks who resigned in March.

• 2

  Prasad is a hematologist-oncologist and professor at UCSF, with over 500 academic articles and two books authored.

• 3

  Andelyn Biosciences developed a novel gene therapy for a baby with NEDAMSS, an ultra-rare condition, within 10 months.

• 4

  Univercells Technologies launched the scale-X nitro controller for bioprocessing, aimed at enhancing viral vector and vaccine production.

• 5

  Cellipont Bioservices partnered with Optieum Biotechnologies for the cGMP manufacturing of a CAR T therapy targeting glioblastoma.